Penumbra Inc (PEN) EVP Sells $261,395.00 in Stock
Penumbra Inc (NYSE:PEN) EVP Lynn Rothman sold 2,273 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $115.00, for a total value of $261,395.00. Following the sale, the executive vice president now owns 154,046 shares of the company’s stock, valued at $17,715,290. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Lynn Rothman also recently made the following trade(s):
- On Tuesday, January 16th, Lynn Rothman sold 6,000 shares of Penumbra stock. The shares were sold at an average price of $90.99, for a total value of $545,940.00.
Penumbra Inc (PEN) opened at $112.95 on Friday. Penumbra Inc has a 12-month low of $74.30 and a 12-month high of $116.35.
Several brokerages have recently weighed in on PEN. William Blair began coverage on Penumbra in a research note on Wednesday, February 21st. They set an “outperform” rating for the company. Canaccord Genuity raised their target price on Penumbra from $100.00 to $113.00 and gave the company a “buy” rating in a research note on Wednesday, November 8th. BMO Capital Markets raised their target price on Penumbra from $110.00 to $115.00 and gave the company a “market perform” rating in a research note on Wednesday. Zacks Investment Research downgraded Penumbra from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. Finally, Wells Fargo & Co raised their target price on Penumbra from $120.00 to $125.00 and gave the company an “outperform” rating in a research note on Wednesday. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $121.67.
Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.